Merck Q3 Preview: Will Earnings Beat Save the Stock?

Merck's profits are soaring, with analysts predicting a 51% jump in Q3 earnings per share, and continued growth through 2026. Despite consistently beating estimates, the healthcare giant's stock has plummeted 22% in the last year, defying the S&P 500's rise. Will upcoming results reverse this trend? Analysts maintain a Moderate Buy rating, forecasting a potential 20% upside.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.